8-K: Aspira Women's Health Secures Mayo Clinic Lab Deal

Aspira Women's Health Inc. has entered into a five-year laboratory services agreement with Mayo Clinic Laboratories to provide its Ova1Plus and OvaWatch tests.

Summary

• Aspira Women's Health Inc. (Aspira) signed a Laboratory Services Agreement with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (Mayo) on December 16, 2025.
• Under the agreement, Aspira will provide its Ova1Plus (Ova1 and Overa) and OvaWatch tests to Mayo on a non-exclusive, as-requested basis for clinical purposes.
• The initial term of the agreement is five years, with automatic one-year renewals, subject to earlier termination by either party.
• Mayo will be responsible for listing Aspira's tests in its catalog, facilitating ordering and delivery of results, and billing for the applicable tests.
• Aspira will invoice Mayo for services performed, with fees remaining fixed during the initial term unless mutually adjusted.
• The agreement includes customary provisions regarding confidentiality, compliance with healthcare laws (including HIPAA), insurance, indemnification, and non-exclusivity.
• The full agreement will be filed once appropriate redactions of immaterial and confidential information are finalized.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the establishment of a significant, multi-year partnership with Mayo Clinic Laboratories, a leading healthcare institution. This agreement provides strong validation for Aspira's diagnostic tests and opens a substantial channel for increased test utilization and revenue, despite the non-exclusive nature.

Positives

• Secured a significant five-year laboratory services agreement with Mayo Clinic Laboratories, a highly reputable institution, which validates Aspira's diagnostic tests.
• The partnership expands the reach and availability of Aspira's Ova1Plus and OvaWatch tests to Mayo's extensive network for clinical purposes.
• Establishes a new revenue stream for Aspira through the provision of reference laboratory testing services to Mayo.

Risks

• The agreement is non-exclusive, meaning Mayo Clinic Laboratories can utilize other providers for similar services.
• Either party can terminate the agreement for convenience with at least ninety days prior written notice, or earlier for cause, introducing potential instability.
• Fees for services are fixed during the initial five-year term, which could limit Aspira's ability to adjust pricing in response to changing market conditions or rising costs.

Future Outlook

The agreement is expected to expand the clinical utilization of Aspira's Ova1Plus and OvaWatch tests through Mayo Clinic Laboratories' network, potentially leading to increased revenue and market penetration for Aspira's diagnostic solutions over the initial five-year term and subsequent renewals.

Management Comments

• The report was duly caused to be signed on behalf of Aspira Women's Health Inc. by Brian Hungerford, Chief Financial Officer, indicating official company endorsement of the agreement.

Industry Context

This agreement positions Aspira Women's Health within the broader trend of diagnostic companies partnering with major healthcare systems and reference laboratories to expand the reach and adoption of specialized tests. Collaborations with highly respected institutions like Mayo Clinic Laboratories are crucial for gaining credibility and market share in the competitive women's health diagnostics sector.

Stakeholder Impact

• Shareholders: Potential for increased revenue and market valuation due to expanded test adoption and partnership with a reputable institution.
• Customers (Mayo patients): Access to Aspira's Ova1Plus and OvaWatch tests through Mayo Clinic Laboratories.
• Employees: Potential for increased workload and operational demands to support the new agreement with Mayo.

Next Steps

• Aspira Women's Health Inc. will file the complete Laboratory Services Agreement as soon as appropriate redactions of immaterial and confidential information are finalized.

Key Dates

Recommendation

The new five-year agreement with Mayo Clinic Laboratories represents a significant positive development for Aspira Women's Health. Partnering with a highly respected institution like Mayo provides strong validation for Aspira's diagnostic tests (Ova1Plus and OvaWatch) and opens a substantial channel for increased test utilization and revenue. This partnership is expected to enhance market penetration and credibility, making the stock a compelling 'buy' for investors seeking growth in the women's health diagnostics sector, despite the non-exclusive nature of the agreement.

Keywords

Aspira Women's Health, Mayo Clinic Laboratories, Laboratory Services Agreement, Ova1Plus, OvaWatch, Diagnostic Tests, Women's Health, SEC Filing, Healthcare Partnership